Medicine and Dentistry
Prostate Cancer
100%
Kidney Cancer
100%
Androgen Deprivation Therapy
66%
Radiation Therapy
66%
Kidney Metastasis
55%
Urinary System
50%
Randomized Clinical Trial
33%
Biological Marker
33%
Bladder Cancer
33%
Kidney Transplantation
33%
Quality of Life
33%
Primary Tumor
33%
Nephrectomy
33%
Local Therapy
33%
Case-Control Study
33%
Decision Making
33%
Transitional Cell Carcinoma
33%
Localized Disease
22%
Neoplasm
22%
Clear Cell Renal Cell Carcinoma
22%
External Beam Radiotherapy
20%
Urinary Tract
20%
Arm
17%
Immune Checkpoint Inhibitor
16%
Combination Therapy
16%
Cohort Analysis
16%
Randomized Controlled Trial
15%
Bladder
13%
Percutaneous Nephrostomy
13%
Shared Decision Making
13%
Systemic Therapy
11%
Disease Management
11%
Systemic Disease
11%
Fibroblast Growth Factor Receptor 2
11%
Phosphotransferase
11%
Fibroblast Growth Factor Receptor
11%
Non Muscle Invasive Bladder Cancer
11%
Vasculotropin
11%
Muscle Invasive Bladder Cancer
11%
Enfortumab Vedotin
11%
Erdafitinib
11%
Clinical Trial
11%
Cisplatin
11%
Programmed Death 1 Ligand 1
11%
Adjuvant Therapy
11%
Neoadjuvant Chemotherapy
11%
Patient Characteristics
10%
Outcome Assessment
10%
Hormone Therapy
10%
Postoperative Complication
6%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
66%
Kidney Cancer
66%
Kidney Metastasis
55%
Progression Free Survival
46%
Overall Survival
45%
Docetaxel
37%
Blood Group A Antigen
33%
Bladder Cancer
33%
Randomized Clinical Trial
33%
Transitional Cell Carcinoma
33%
Prostate Specific Antigen
33%
Biological Marker
33%
Bicalutamide
33%
Primary Tumor
33%
Renal Cell Carcinoma
27%
Cohort Study
25%
Combination Therapy
25%
Immune Checkpoint Inhibitor
25%
Neoplasm
22%
Clinical Trial
15%
Chemotherapy
14%
Erdafitinib
11%
Enfortumab Vedotin
11%
Cisplatin
11%
Non Muscle Invasive Bladder Cancer
11%
Muscle Invasive Bladder Cancer
11%
Fibroblast Growth Factor Receptor
11%
Phosphotransferase
11%
Fibroblast Growth Factor Receptor 2
11%
Programmed Death 1 Ligand 1
11%
Vasculotropin
11%
Endocrine Therapy
10%
Androgen
8%
Immunotherapy
8%
Protein Tyrosine Kinase Inhibitor
8%
Vasculotropin Receptor
8%
Randomized Controlled Trial
8%
Protein Tyrosine Kinase
8%
Systemic Treatment
8%
Comorbidity
6%
